vTv Therapeutics (NASDAQ:VTVT) Upgraded at Evercore

vTv Therapeutics (NASDAQ:VTVT) was upgraded by equities research analysts at Evercore to a “strong-buy” rating in a research report issued on Thursday,Zacks.com reports.

Several other equities research analysts have also issued reports on VTVT. TD Cowen began coverage on vTv Therapeutics in a research note on Monday, January 5th. They issued a “buy” rating for the company. BTIG Research reiterated a “buy” rating and issued a $49.00 target price on shares of vTv Therapeutics in a research note on Wednesday. Roth Mkm began coverage on vTv Therapeutics in a research report on Thursday, January 22nd. They set a “buy” rating and a $58.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday, December 29th. Finally, Wall Street Zen raised shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.00.

vTv Therapeutics Stock Down 1.3%

vTv Therapeutics stock opened at $33.28 on Thursday. vTv Therapeutics has a 52-week low of $14.00 and a 52-week high of $44.00. The firm’s fifty day moving average is $35.93 and its 200 day moving average is $29.42. The company has a market cap of $131.12 million, a price-to-earnings ratio of -9.93 and a beta of 0.44.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings data on Tuesday, March 10th. The biotechnology company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.51. The business had revenue of ($0.02) million during the quarter.

Institutional Trading of vTv Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Baker BROS. Advisors LP grew its holdings in vTv Therapeutics by 52.4% during the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after acquiring an additional 51,000 shares in the last quarter. 683 Capital Management LLC bought a new stake in shares of vTv Therapeutics in the 4th quarter valued at about $731,000. Geode Capital Management LLC lifted its position in shares of vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares during the period. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of vTv Therapeutics in the 4th quarter worth approximately $221,000. 17.51% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting vTv Therapeutics

Here are the key news stories impacting vTv Therapeutics this week:

• Positive Sentiment: Evercore ISI initiated coverage with an “Outperform” recommendation, providing a new institutional buy-side endorsement that can attract demand and support the share price. Evercore initiation article
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and $47 price target while raising several near-term EPS estimates (Q1–Q4 2026 and FY2026) and trimming losses for FY2027 relative to prior forecasts — a signal that the firm sees improving fundamentals in the nearer term and provides supportive analyst cover (no link available).
• Neutral Sentiment: vTv filed Q4 and full-year 2025 financial results and issued a corporate update; company results and commentary can influence sentiment depending on guidance and program milestones, so investors should review the release for pipeline/cash details. Q4/FY2025 results and corporate update
• Neutral Sentiment: Market calendars show vTv is projected to announce upcoming earnings — scheduled event risk can increase intraday volatility around the stock. Earnings projection article
• Negative Sentiment: Within the same HC Wainwright coverage notes, the firm lowered long‑range EPS assumptions (FY2028–FY2030 and FY2029 reductions), increasing projected longer-term losses. Those cuts could pressure expectations for longer-term profitability and cap upside despite near-term improvements (no link available).

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.